Effect of changing from first- to second- line antiretroviral therapy on renal function : a retrospective study based on data from a single health facility in Namibia

Kalemeera, Francis and Mbango, Christofina and Mubita, Mwangana and Naikaku, Esther and Gaida, Razia and Godman, Brian (2016) Effect of changing from first- to second- line antiretroviral therapy on renal function : a retrospective study based on data from a single health facility in Namibia. Expert Review of Anti-infective Therapy. ISSN 1744-8336 (In Press)

[thumbnail of Kalemeera-etal-ERAIT-2016-Effect-of-changing-from-first-to-second-line-antiretroviral-therapy-on-renal]
Preview
 Text. Filename: Kalemeera_etal_ERAIT_2016_Effect_of_changing_from_first_to_second_line_antiretroviral_therapy_on_renal.pdf
Accepted Author Manuscript
Download (719kB)| Preview

Abstract

Tenofovir disoproxil fumarate (TDF) and lopinavir/ritonavir (LPV/r) can cause renal impairment with this combination co-administered during second-line combination antiretroviral therapy (cART) potentially associated with greater risk of nephrotoxicity. Objective: Assess effects of second-line cART on renal function. Methods: Retrospective longitudinal study in patients receiving cART. Results: 71 patients received TDF, zidovudine or stavudine, each combined with 3TC/NVP or 3TC/ EFV. Before second-line cART, 46.5% had abnormal kidney function. First-line cART had no relationship with calculated creatinine clearance (CrCl). During second-line cART, more males than females had abnormal renal function and more females experienced increases in CrCl. Calculated CrCl during second-line cART related strongly with CrCl during first-line cART; time spent on cART weak relationship with CrCl. Conclusion: Patients on first-line cART for several years without renal impairment may experience new onset impairment during cART. Patients with pre-existing renal impairment just before switching to second-line cART may experience a further decline.

CORE (COnnecting REpositories)